CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity.

Westermann, J; Nguyen-Hoai, T; Baldenhofer, G; Höpken, U E; Lipp, M; Dörken, B; Pezzutto, A

Westermann, J; Nguyen-Hoai, T; Baldenhofer, G; Höpken, U E; Lipp, M; Dörken, B; Pezzutto, A.

Affiliation

Westermann J; Department of Hematology, Charité - University Medicine Berlin, Campus Berlin-Buch, Berlin, Germany. joerg.westermann@charite.de

Cancer Gene Ther ; 14(6): 523-32, 2007 Jun.

Article in En | MEDLINE | ID: mdl-17384577

Subject(s)

Antineoplastic Agents/immunology; Chemokines, CC/immunology; Dendritic Cells/drug effects; Neoplasms/therapy; T-Lymphocytes/drug effects; Vaccines, DNA/immunology; Adjuvants, Immunologic/administration & dosage; Animals; Antineoplastic Agents/administration & dosage; Cell Line, Tumor; Chemokine CCL19; Chemokines, CC/administration & dosage; Dendritic Cells/immunology; Disease Models, Animal; Mice; Mice, Inbred C57BL; Neoplasms/immunology; T-Lymphocytes/immunology; Th1 Cells/immunology; Th1 Cells/metabolism; Vaccination; Vaccines, DNA/administration & dosage

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Dendritic Cells / T-Lymphocytes / Vaccines, DNA / Chemokines, CC / Neoplasms / Antineoplastic Agents Limits: Animals Language: En Year: 2007 Type: Article

Search on Google

XML

PubMed Links